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Background/aim: Comorbidity of depression in Parkinson disease (PD) is a major factor that changes patients’ quality of life. However,
the neurobiological and sociodemographic risk factors for this comorbidity are not well studied. In this study, we aimed to define the
prevalence, temporal relationship, and psychosocial and clinical determinants of depression comorbid with PD.
Materials and methods: Fifty-five PD patients were evaluated with SCID, a data form that assessed sociodemographic and PD-related
variables, UPDRS III, HAM-D, HAM-A, MMSE, and the Apathy Evaluation Scale.
Results: Depression (lifetime: 45.5%, last month: 25.5%, before PD: 20%) was the most frequent psychiatric diagnosis. The major
determinants of depression in the last month and depression before PD were early onset of PD and young age. Patients on pramipexole
treatment were less likely to be diagnosed with depression in the last month. Other sociodemographic and PD-related variables were not
significantly different for lifetime, last month, and pre-PD depression diagnosis compared to their counterparts.
Conclusion: Depression is prevalent both before and after patient gets a PD diagnosis. Depression is not only the result of PD-related
life changes but it is also a preceding factor that may decrease the age of PD onset.
Key words: Parkinson disease, depression, pramipexole, age of onset

1. Introduction
Parkinson disease (PD), which was primarily defined and
diagnosed according to the existence of motor symptoms
(1), is receiving much more attention by having a prevalence
of 1.8% among people aged over 60 (2). As new treatments
for the disease have emerged, the expected time to live after
diagnosis has reached up to more than 12 years (3) and
nonmotor symptoms have been much more prominent and
important to recognize. Nonmotor symptoms like pain,
anxiety, and depression are also major factors that affect
quality of life (4,5) and perceived stress (6), and they are
crucial measures in the follow-up of PD.
Among the psychiatric disorders comorbid with PD,
depression has the highest prevalence, followed by anxiety
disorders, sleep disorders, and others (7). Patients with
a PD diagnosis have a 1.89–4.26 times increased risk of
depression (8,9). Despite this high risk and prevalence,
studies conducted so far were not able to conclude the effect
of depression on PD prognosis, the temporal relationship
of the two disorders, and the determinants of depression in
PD patients. Low socioeconomic status, cognitive deficits,
laterality of PD motor symptoms, and anxiety disorder
* Correspondence: heser@kuh.ku.edu.tr

comorbidity were shown to increase depression vulnerability
in PD patients (10–12). First-degree relatives of PD patients
also have a higher risk of depressive and anxiety disorders
(13), which indicates a neurobiological susceptibility. On the
other hand, PD patients face many psychosocial stressors in
having a chronic and progressive illness or disability (14,15),
which creates an environmental risk.
In order to reach a clear conclusion about the PD/
depression connection, knowing the temporal relationship
and determinants of depression could help resolve the
question of whether depression is the cause, prodrome,
or result of PD. In this study, we aimed to determine the
temporal relationship of depression and PD; to find the
prevalence and determinants of lifetime depression (LD),
depression in the last month (DLM), and depression before
PD (DBPD) diagnosis; and to define the determinants for
each type of depression diagnosis.
2. Materials and methods
2.1. Participant selection and evaluation
Patients who agreed to take part in the study and met
the United Kingdom Parkinson’s Disease Society Brain
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Bank Clinical Diagnostic Criteria were recruited from the
Movement Disorders Clinic of Gazi University. For the
55 eligible patients, a sociodemographic data form was
administered regarding PD age of onset and duration, side
of onset, presenting symptom, symptom lateralization,
personal and family history of psychiatric diagnosis,
treatments for PD, and other medical diagnoses as well
as variables like age, marital status, and monthly income.
In addition, the SCID-Clinical Version, Mini Mental State
Exam Test (MMSE), Hamilton Depression (HAM-D) and
Hamilton Anxiety Scales (HAM-A), clinician version
of the Apathy Evaluation Scale (AES), and Unified
Parkinson’s Disease Rating Scale part III (UPDRS III)
were used to detect the psychiatric diagnosis, severity
of motor symptoms, and other psychosocial predictors.
Depression diagnosis before PD, lifetime depression
diagnosis, and depression diagnosis in the last month
were evaluated by the SCID interview. Hospital reports
and information from the caregiver were also taken when
needed. The Gazi University Faculty of Medicine Ethics
Committee approved the study. All participants provided
written informed consent. Data regarding the participant
characteristics can be found in Table 1.
2.2. Statistical methods
Clinical data were analyzed with the Mann–Whitney U
test for continuous variables and the chi-square test for
categorical variables. In order to assess the determinants of
depression, patients that had a depression diagnosis before
PD (DBPD, n = 11) were compared to the patients that did
not have a DBPD diagnosis (non-DBPD, n = 44), patients
that had a lifetime depression diagnosis (LD, n = 25) were
compared to the patients that did not have a LD diagnosis
(non-LD, n = 30), and patients that had a depression
diagnosis in the last month (DLM, n = 14) were compared
to the patients that did not have a DLM diagnosis (nonDLM, n = 41). P < 0.05 was considered significant.
3. Results
Of the 55 patients, 15 patients (27.2%) were currently using
antidepressants, 11 patients (20%) had DBPD, 25 patients
(45.5%) had LD, and 14 patients (25.5%) had DLM. Of
the 25 patients that had a lifetime depression diagnosis, 6
patients were diagnosed with depression after PD diagnosis
and they were currently in remission, 5 patients had a
depression diagnosis only before PD and were currently
in remission, 8 patients only had a depression diagnosis in
the last month, and 6 patients had a depression diagnosis
both before PD and in the last month. Generalized anxiety
disorder (40%) was the second most common psychiatric
diagnosis. A list of psychiatric diagnoses can be found in
Table 2. None of the patients had an apathy score higher
than 42.
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None of the sociodemographic variables like sex,
marital status, working status, and monthly income were
significantly different between DBPD and non-DBPD
groups, LD and non-LD groups, and DLM and non-DLM
groups (P > 0.05). Variables regarding clinical features
of PD such as side of onset, presenting symptoms, PD
symptom lateralization, duration of PD diagnosis, and
other clinical evaluation scales were not significantly
different among the groups. However, DBPD patients were
significantly younger than non-DBPD patients (56.5 ± 12
vs. 66.7 ± 9 years, P = 0.01) and they also had younger age
of PD onset (51.9 ± 13 vs. 60.47 ± 9 years, P = 0.04).
DLM patients were also significantly younger (60 ±
8 vs. 66 ± 11 years, P = 0.03) and had significantly lower
age of PD onset (53 ± 7 vs. 60.7 ± 10.7 years, P = 0.01)
than non-DLM patients. In addition to this, depressed PD
patients had higher HAM-A (9.5 ± 6 vs. 5.6 ± 7, P = 0.03)
and AES (39.9 ± 11 vs. 32.8 ± 12, P = 0.05) scores, but
none of the depressed patients’ scores were high enough
to be diagnosed with an anxiety disorder or apathy
(Supplementary Table 1).
Even though levodopa equivalent doses of PD
treatments were not different among the groups (517 ±
290 mg for non-DLM and 617 ± 201 mg for DLM, P =
0.38), based on the depression diagnosis in the last month,
patients that were on ropinirole hydrochloride treatment
were more likely to be diagnosed with depression (50%
and 21%, respectively; P = 0.046) and patients that were
on pramipexole treatment were less likely to be diagnosed
with depression (7% and 36%, respectively; P = 0.036).
There was not a significant difference among the patients
diagnosed with DLM and non-DLM for antidepressant
use (P > 0.05).
4. Discussion
According to the results of this study, depression is highly
comorbid with PD both before and after PD diagnosis
and it is more common than other psychiatric disorders.
These results are in accordance with previous studies that
reported a higher number of depression diagnoses in
PD patients (3,7,8,16), and this comorbidity is 4–5 times
higher than expected for the general population or elderly
population (17) with even higher prevalence of depression
in inpatient samples in Turkey (18).
By investigating lifetime, last month, and before PD
diagnoses of depression, we could show that depression is
not only a phenomenon that follows the PD diagnosis but
it may also be a prodromal feature. Of the 45.5% of the
PD patients with a lifetime depression diagnosis, 44% had
depression before PD, which supports the hypothesis that
depression is not just a result of the physical disturbances
and psychosocial stressors associated with the disease.
The fact that depression in PD is also higher than in
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Table 1. Sociodemographic and clinical variables of participants.
Sex (female/male)

21/34

Marital status (married/divorced/widowed)

49/1/5

Educational status (secondary school and lower/high school and higher)

24/31

Dominant hand (right/left)

54/1

Number of comorbid diseases (0/1/2/>3)

22/24/6/3

Side of onset (right/left/bilateral)

27/25/3

Presenting symptom (tremor/rigidity/unknown)

32/22/1

Major depression before PD diagnosis (yes/no)

11/44

Age (years)

64.7 ± 10

Age at PD onset (years)

58.7 ± 10

Duration of PD symptoms (months)

71.2 ± 49.7

MMSE

27.8 ± 3

HAM-D

8.5 ± 8

HAM-A

6.6 ± 7

Apathy Evaluation Scale

34.6 ± 12

UPDRS III

13.4 ± 8

Table 2. Lifetime and last month psychiatric diagnosis of the participants.
Lifetime psychiatric diagnosis (n = 35)

Number

%

Major depression

25

71.4

Generalized anxiety disorder

11

31.4

Dysthymia

3

8.6

Panic disorder

2

5.7

Obsessive compulsive disorder

2

5.7

Posttraumatic stress disorder

2

5.7

Agoraphobia

1

2.9

Adjustment disorder

1

2.9

Psychiatric diagnosis in the last month (n = 25)

Number

%

Major depression

14

56

Generalized anxiety disorder

10

40

Dysthymia

3

12

Posttraumatic stress disorder

1

4

Agoraphobia

1

4

Adjustment disorder

1

4

other diseases with a chronic course, e.g., osteoarthritis
or diabetes mellitus, that result in physical disabilities (19)
also supports these results.
We found that duration of PD symptoms was not
related to depression, which supports the idea that
depression might be a neuropathological process
occurring concomitantly or before the degeneration of

motor systems. Presenting symptoms of PD were also not
different among the groups, even though some studies
reported higher depression prevalence among patients
with tremor as the presenting symptom (2,20). One study
(12) also found a negative association with tremor onset
and depression. However, we have observed a significant
medication effect: patients on pramipexole treatment were
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less likely to be diagnosed with depression. It is suggested
that by its agonist activity on D3 receptors, pramipexole
might have a positive effect on the treatment of depressive
symptoms (21–24). On the other hand, ropinirole, which
is a monoamine oxidase inhibitor, was not protective
against depression; this finding is contrary to animal and
human studies that supported an antidepressant effect for
ropinirole (25,26). The other PD agents that the patients
were using may have led to this finding.
Among the investigated psychosocial determinants of
depression before PD diagnosis and depression in the last
month, young age of onset and mean age were significantly
different between the groups. Early-onset PD patients
have longer disease durations, experience nonmotor
symptoms more often, retire earlier, and have to deal more
often with marital and occupational problems (27), and
that may explain higher rates of depression diagnosis in
the last month. However, it is also known that chronic
stress and mood disorders may lead to neurodegenerative
changes in the brain as defined in Alzheimer disease (28).
Glucocorticoids that are released in response to stress may
increase the loss of dopaminergic neurons in PD (29).
Thus, depression might also be a factor that accelerates the
onset of PD in vulnerable patients. A recently published
cohort study also showed that having prior depression
increases the risk of having a PD diagnosis in the following
year by 3.2 times (30). In animal models where depression
is modeled by chronic stress paradigms, increased HPA
axis and oxidative stress, increased dendritic atrophy,

decreased neurogenesis, and increased inflammation
are shown (31,32). Each of these neuropathological
mechanisms of depression may trigger or effect the onset
of PD and should be investigated further in future studies.
On the other hand, this study has limitations in
addition to its strengths. The patients that took part in
this study were patients in the middle phase of the disease
(mean duration of illness for the sample was 71.2 months),
were nondemented, and had lower levels of disability,
and the research sample was relatively small, which may
prevent generalization of the results for the whole PD
disease duration. However, a trained physician evaluated
all patients with a structured face-to-face interview and
hospital records were taken into account if needed, instead
of using self-evaluation scales. We think that the only way
to get more reliable information about the depression/PD
temporal relationship is by including nondemented PD
patients. Depression was studied for diagnoses before PD,
lifetime depression, and diagnoses in the last month and
confounding factors like apathy and anxiety were assessed
carefully, which is a major strength. Since our patient
group had low anxiety and apathy scores, we could present
a more clear view for the presentation of depression.
In conclusion, depression is prevalent both before
and after PD diagnosis and it may be a preceding factor
that decreases the age of onset of vulnerable PD patients.
Further studies with larger sample sizes and examination
of the effect of depression on PD progression in animal
models are needed to replicate the results of this study.
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Supplementary Table 1. Sociodemographic variables and clinical scale scores of research groups.
Mean

Std. dev.

Mean

Std. dev.

Depression diagnosis before Parkinson disease (DBPD)

DBPD- (n = 44)

DBPD+ (n = 11)

P

Age (years)

66.75

9.34

56.55

12.35

0.01

Education level (years)

9.30

4.75

9.73

4.76

0.81

Age of PD onset (years)

60.47

9.07

51.91

13.03

0.04

Months since PD onset

75.14

52.04

55.64

37.38

0.33

MMSE score

27.64

3.07

28.55

2.34

0.23

HAM-D score

7.25

6.94

13.55

9.94

0.07

HAM-A psychological subscale score

3.05

3.17

3.45

3.05

0.52

HAM-A somatic subscale score

3.23

4.23

4.73

3.88

0.14

HAM-A total score

6.27

7.11

8.18

6.29

0.25

Apathy Evaluation Scale score

34.93

11.93

33.64

13.03

0.70

UPDRS III score

13.98

7.92

11.20

7.15

0.43

Lifetime depression diagnosis (LD)

LD- (n = 30)

Age (years)

65.67

8.70

63.56

12.81

0.55

Education level (years)

9.73

4.35

8.96

5.17

0.46

Age of PD onset (years)

60.48

8.69

56.68

12.06

0.20

Months since PD onset

61.80

47.22

82.56

51.33

0.09

MMSE score

27.87

2.53

27.76

3.43

0.66

HAM-D score

4.73

3.77

13.04

9.25

0.00

HAM-A psychological subscale score

3.33

3.43

2.88

2.76

0.78

HAM-A somatic subscale score

3.20

4.18

3.92

4.20

0.44

HAM-A total score

6.53

7.38

6.80

6.54

0.72

Apathy Evaluation Scale score

32.70

11.73

37.04

12.22

0.17

UPDRS III score

13.48

8.10

13.39

7.56

0.83

Depression diagnosis in the last month (DLM)

DLM- (n = 41)

DLM+ (n = 14)

P

Age (years)

66.32

11.03

60.00

8.37

0.03

Education level (years)

9.22

4.75

9.86

4.74

0.83

Age of PD onset (years)

60.71

10.77

53.04

6.96

0.01

Months since PD onset

67.02

49.40

83.57

50.61

0.22

MMSE score

27.59

3.15

28.50

2.18

0.32

HAM-D score

4.54

3.94

20.14

4.33

0.00

HAM-A psychological subscale score

2.76

3.24

4.21

2.55

0.07

HAM-A somatic subscale score

2.88

4.06

5.36

4.22

0.02

HAM-A total score

5.66

6.97

9.57

6.21

0.03

Apathy Evaluation Scale score

32.88

11.82

39.93

11.51

0.05

UPDRS III score

13.13

8.37

14.50

5.66

0.22

LD+ (n = 25)

P

1

